Irinotecan Hydrochloride Seacross Pharmaceuticals

Irinotecan hydrochloride, the active ingredient in Irinotecan Hydrochloride Seacross Pharmaceuticals, is a topoisomerase I inhibitor presented as a sterile powder for intravenous use. It is employed in the treatment of colorectal cancer, including metastatic disease, and is administered under the supervision of oncology specialists.

GNH USA supplies Irinotecan Hydrochloride Seacross Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan hydrochloride is used in chemotherapy regimens targeting colorectal malignancies.

Colorectal cancer: administered as part of combination chemotherapy to inhibit tumor growth. Metastatic colorectal cancer: used to improve survival in patients with metastatic disease. Advanced colorectal carcinoma: employed when disease has progressed after first‑line therapy.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Diarrhea: may be severe and require supportive care. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: general tiredness and weakness. - Alopecia: hair loss during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent medical attention. - Severe colitis: intense inflammation of the colon. - Allergic reactions: rash, itching, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes or liver dysfunction. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Prior to initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for toxicity.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: adjust dosing in hepatic impairment. Hydration: ensure adequate fluid intake to mitigate diarrhea. Pregnancy: avoid use unless potential benefit justifies risk. Drug interactions: review concomitant medications for CYP3A4 inhibitors. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase irinotecan exposure and toxicity. - UGT1A1*28 homozygous genotype: heightened risk of severe neutropenia and diarrhea. - Concurrent myelosuppressive agents: can exacerbate bone marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect metabolism of irinotecan. - Warfarin: monitor INR for potential anticoagulation changes. - Fluoropyrimidines: increased risk of gastrointestinal toxicity.